CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
Meet Martina Wood a breast cancer survivor and a member of the CCTG breast committee. Our teams are proud to work with volunteers like Martina who ensure the patient voice is part of our clinical trial development.
The UK National Cancer Research Institute (NCRI) has cited the CCTG PR13 study (RADICALS-RT) as one of their top three achievements of the year in their 2019-2020 annual report! https://www.ncri.org.uk/wp-content/uploads/NCRI-Prostate-Group-Annual-Report-2019-20.pdf
A paper has recently been published in Current Oncology outlining the incorporation of patient engagement in the development of clinical trial at the Canadian Cancer Trials Group (CCTG).
A recent abstract presented at GI ASCO 2021: Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
CCTG SR7: A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS-2), has been centrally activated.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
For our Canadian member sites a COVID-19 reminder to keep the CCTG updated on trial activities at your site.
The Regulatory Affairs Team Leader will lead the Regulatory Team for CCTG within the OCO. The core responsibilities include leadership to ensure compliance with national and international regulations essential to the compliant conduct of clinical trials, development and implementation of Standard Operating Procedures at the Operations and Statistics Centre at Queen's University and in support of partnering organizations, and providing guidance in alignment with CCTG strategic directions.
